Vonjo ( paracrit for myelofibrosis – pro
Vonjo (pacritinib) is FDA approved d to treat adults with myelofibrosis (MF) when their platelet count is below 50,000 per microliter. NCCN recommends it for higher-risk MF as Category 2.
John Mascarenhas, MD; Ronald Hoffman, MD; Moshe Talpaz, MD et al, Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With MyelofibrosisA Randomized Clinical Trial. JAMA Oncol Published Online: May 2018 2018;4;(5):652-659. doi:10.1001/jamaoncol.2017.5818
Verstovsek S, Komrokji RS. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 2015;11(20):2819-30. doi: 10.2217/fon.15.200. Epub 2015 Sep 14. PMID: 26367195; PMCID: PMC4918816.
Guideline/Criteria References:
NCCN MF-2 2025